Vicky Makker

25PUBLICATIONS
205CO-AUTHORS
Molecular targetsFood properties (incl. characteristics and health benefits)Predictive and prognostic markersForensic epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 27, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

|May 26, 2026
Very low-carbohydrate ketogenic diet in treatment-naïve women with endometrial cancer and overweight: a randomized feasibility study.

|May 15, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.

|Apr 09, 2026
Post Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors.

Vicky Makker, Jung-Yun Lee, Do-Youn Oh

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

|Feb 19, 2026
Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado

Pageof 5

Frequent Collaborators

9 joint publications

Britta Weigelt

5 joint publications

Alexia Iasonos

5 joint publications

Ana Oaknin

4 joint publications

Jung-Yun Lee